OOIR: Observatory of International Research

Papers

(The TQCC of Blood Reviews is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	152
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	115
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	111
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	110
Editorial Board	103
Not all LGL leukemias are created equal	87
Radiation and leukaemia: Which leukaemias and what doses?	77
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	65
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	60
Clinical burden of hemophilia in older adults: Beyond bleeding risk	58
Artificial intelligence in sickle disease	54
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	52
Thalassaemia in China	52
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	49
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	46
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	44
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	44
Chasing leukemia differentiation through induction therapy, relapse and transplantation	41
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	38
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	38
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	36
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	36
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	36
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	35
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	35

Endothelial cells: major players in acute myeloid leukaemia	34
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	33
Immune thrombocytopenia: A review of upfront treatment strategies	32
Preservation of fertility in female patients with hematologic diseases	32
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	31
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	31
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	30
CHIPing away the progression potential of CHIP: A new reality in the making	30
Coagulation and anticoagulation in COVID-19	30
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	29
Down syndrome and leukemia: An insight into the disease biology and current treatment options	29
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines	28
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria	28
Current challenges in conditioning regimens for MDS transplantation	28
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	27
The extracellular matrix: A key player in the pathogenesis of hematologic malignancies	27
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia	27
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma	26
Richter's transformation: Transforming the clinical landscape	26
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation	25
Management of venous thromboembolism in athletes	25
Optimizing high dose melphalan	24
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?	24
Complementary and alternative medicine for children with sickle cell disease: A systematic review	24
The mythological chimera and new era of relapse prediction post-transplant	23
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia	23
Αlpha-thalassemia: A practical overview	23
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis	21
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease	21
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy	21
Current state and next-generation CAR-T cells in multiple myeloma	21
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned	21
Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement	20
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape	20
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy	19
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion	19
Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies	19
AML and the art of remission maintenance	19
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	19
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	18
Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies	18
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	18
Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients	18
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	18
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency	17
Innovations in red blood cell preservation	17
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	17
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	17
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia	17
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?	16

The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence	16
Discussing investigational AAV gene therapy with hemophilia patients: A guide	16
The use of bone-modifying agents in multiple myeloma	16